USANA Health Sciences, Inc. announced that consistent with the Company's planned succession strategy, Kevin Guest, USANA's Chief Executive Officer (CEO) since 2015 and Chairman of the Board since 2020, will transition to the role of Executive Chairman of the Company, effective July 1, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
47.4 USD | +1.49% | +6.31% | -11.52% |
May. 07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
May. 01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.52% | 890M | |
+16.80% | 8.43B | |
+15.02% | 6.82B | |
-4.09% | 3.77B | |
-6.75% | 3.74B | |
+4.41% | 1.44B | |
-25.85% | 1.06B | |
+20.28% | 1.04B | |
-16.89% | 812M | |
+2.88% | 732M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- Kevin Guest to Transit to the Role of Executive Chairman of USANA Health Sciences, Inc., Effective July 1, 2023